Exelixis, Inc. (EXEL) key performance indicators and operating metrics (11 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Collaboration revenues | 55.8M | FY2026-Q1 |
| Cabozantinib Franchise United States Net Product Revenues | 553.9M | FY2026-Q1 |
| Non-GAAP Net Income | 232.8M | FY2026-Q1 |
| COMETRIQ net product revenues (U.S.) | 2.2M | FY2026-Q1 |
| Royalty revenues | 45.9M | FY2026-Q1 |
| Non-GAAP EPS (diluted) | 0.87 USD_per_share | FY2026-Q1 |
| Selling, general and administrative expenses | 139.6M | FY2026-Q1 |
| Provision for income taxes | 57.2M | FY2026-Q1 |
| COMETRIQ net product revenues | 3.1M | FY2025-Q3 |
| Royalty revenues (cabozantinib-related) | 46.3M | FY2025-Q3 |
| Research and development expenses | 199.2M | FY2025-Q3 |
Back to EXEL overview · EXEL earnings · EXEL holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.